(Reuters) – Moderna Inc on Wednesday agreed to buy Japan-based OriCiro Genomics for $85 million to boost the U.S. drugmaker’s mRNA manufacturing capabilities.
OriCiro’s technologies will support Moderna’s portfolio of therapeutics and vaccines, the companies said.
(Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)
